JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glenn, D. J.
Right arrow Articles by Maurer, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glenn, D. J.
Right arrow Articles by Maurer, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 51, 36159-36167, December 17, 1999


MRG1 Binds to the LIM Domain of Lhx2 and May Function as a Coactivator to Stimulate Glycoprotein Hormone alpha -Subunit Gene Expression*

Denis J. GlennDagger and Richard A. Maurer§

From the Department of Cell and Developmental Biology, Oregon Health Sciences University, Portland, Oregon 97201

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Tissue-specific expression of the alpha -subunit gene of glycoprotein hormones involves an enhancer element designated the pituitary glycoprotein basal element, which interacts with the LIM homeodomain transcription factor, Lhx2. In the present studies we have explored the function of the LIM domain of Lhx2 in stimulating alpha -subunit transcription. When fused to the GAL4 DNA-binding domain, the LIM domain of Lhx2 was shown to contain a transcriptional activation domain. Furthermore, in the context of an alpha -subunit reporter gene in which a GAL4-binding site replaced the pituitary glycoprotein basal element, the LIM domain enhanced both basal and Ras-mediated transcription. In addition, a synergistic response to Ras activation was observed when the Lhx2 LIM domain and the transactivation domain of Elk1 are directed to a minimal reporter gene. A yeast two-hybrid screen identified the recently described melanocyte-specific gene-related gene 1 (MRG1) as an Lhx2 LIM-interacting protein. MRG1 was shown to bind Lhx2 in vitro, and a co-immunoprecipitation assay provided evidence that endogenous MRG1 forms a complex with Lhx2 in alpha T3-1 cells. Expression of MRG1 in alpha T3-1 cells enhanced alpha -subunit reporter gene activity. MRG1 was also shown to bind in vitro to the TATA-binding protein and the transcriptional coactivator, p300. These data suggest a model in which the Lhx2 LIM domain activates transcription through interaction with MRG1 leading to recruitment of p300/CBP and the TATA-binding protein.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Members of the LIM homeodomain family of transcription factors have been shown to contribute to the regulated expression of the alpha -subunit of the glycoprotein family of hormones (1). The ability of the pituitary to secrete the gonadotropic hormones, follicle-stimulating hormone, and luteinizing hormone is crucial for normal reproductive function. The synthesis and secretion of the gonadotropins is regulated by the hypothalamic hormone, gonadotropin-releasing hormone (GnRH),1 which acts to increase gonadotropin subunit mRNA levels (2-9) through effects at the transcriptional level (10, 11).

LIM homeodomain factors appear to play a role in both basal and GnRH-stimulated expression of the glycoprotein hormone alpha -subunit gene (1, 12). Initial studies demonstrated that LIM homeodomain factor-2 (Lhx2, also designated LH-2) can bind to a pituitary-specific enhancer element designated the PGBE of the mouse alpha -subunit gene (1). Because both the PGBE and a separate, structurally distinct DNA element designated the GnRH-RE are required for GnRH responsiveness of the mouse glycoprotein hormone alpha -subunit promoter (12), the finding that Lhx2 binds to the PGBE implies that this LIM factor plays a role in transcriptional responses to GnRH. It has also been shown that a related LIM factor, Lhx3 (also designated pLIM or LIM3) can also enhance alpha -subunit gene expression (13). Targeted disruption of the Lhx3 gene in mouse results in loss of pituitary organogenesis (14), demonstrating that LIM factors also play an important developmental role in the formation of the pituitary.

The specific role that the LIM domains play in transcriptional activation is somewhat unclear. The LIM domain, named for the genes of the first three members of the family, lin-11 (15), isl-1 (16), and mec-3 (17), is characterized by the presence of two zinc finger motifs that involve cysteine and histidine or aspartate residues that tetrahedrally coordinate a zinc atom (18, 19). There is evidence that some LIM domains can inhibit DNA binding of the associated homeodomain (20-22). This would suggest that the LIM domain may negatively regulate LIM factor activity. However, it is not clear that inhibition of DNA binding is a general phenomenon for LIM factors (23). Functional studies of Xlim-1 in Xenopus laevis have shown that deletion or mutation of the LIM domain of Xlim-1 results in the induction of secondary axis formation, whereas the wild type factor has no effect (24). This has been interpreted as evidence for a negative role for the LIM domain in regulating transcription. However, in the absence of more mechanistic information about Xlim-1 action, other interpretations are possible. In contrast to the view that LIM domains play a negative role in regulating DNA binding and transcription, some LIM factors have been shown to demonstrate synergistic transcriptional activation with other transcription factors (13, 25).

Recently, a putative co-activator was identified independently in several labs that binds to members of the LIM homeodomain protein family and nuclear LIM only proteins (24, 26, 27). This LIM-binding protein has been termed NLI (nuclear LIM interactor), LIM domain-binding factor and cofactor of LIM domain proteins. It has been suggested that NLI may have a positive effect on transcription by relieving the inhibitory effects of the LIM domain in the context of the full-length Xlim-1 in vivo (28). However, NLI has also been shown to inhibit the synergy between the LIM homeodomain factor Lmx-1 and the basic helix-loop-helix transcription factor, E47 (29). Thus, like the LIM domain itself, it is not yet clear whether NLI plays a positive or negative role in mediating or regulating LIM factor function.

In the present studies we sought to further define the function of the LIM domain of Lhx2 in the transcription of the glycoprotein alpha -subunit gene. We have shown the LIM domain of Lhx2 is sufficient to activate transcription when directed to the PGBE of the alpha -promoter. Furthermore, we have identified a LIM-interacting transcriptional activator, MRG1, that is capable of mediating enhanced transcription of the alpha -promoter.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reporter Genes and Expression Constructs-- Luciferase reporter genes containing the -507 to +46 region of the mouse glycoprotein hormone alpha -subunit gene or the -507 to -205 region linked to a minimal promoter have been described previously (12, 30). The PGBE and GnRH-RE mutant alpha -subunit luciferase reporter genes were constructed by subcloning double-stranded oligonucleotides containing the GAL4-binding site, GGAAGACTCTCCTCCG, into the NotI restriction site of the previously described block PGBE and GnRH-RE mutant alpha -subunit promoter constructs (30). The 5× GAL4-binding site luciferase reporter and the GAL4-Elk1 expression constructs have been described previously (31). The mutant GAL4-Elk1 S383A expression vector was constructed by oligonucleotide-directed mutagenesis using standard techniques to remove a major MAPK phosphorylation site (32). To prepare GAL4-LIM domain and GAL4-NLI expression constructs, the appropriate coding regions were isolated by polymerase chain amplification and subcloned into the pcDNA3 vector (Invitrogen) containing the GAL4(1-147) DNA-binding domain downstream of the cytomegalovirus promoter (33). For construction of an MRG1 expression vector, the complete coding sequence for MRG1 was isolated by polymerase chain reaction amplification from alpha T3-1 cell cDNA using primers based on the known sequence (34), and the coding sequence was cloned into pcDNA3. The Lhx2 LIM and MRG1 maltose-binding protein (MBP) fusion constructs were generated by subcloning appropriate fragments into the bacterial expression vector pMAL-c2 (New England Biolabs).

Cell Culture and Transfections-- alpha T3-1 and NS20Y cells were maintained in monolayer culture in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Life Technologies, Inc.). For transient transfection assays cells were plated in 6-well plates 24 h prior to transfection and then treated with a suspension of 5-10 µl of LipofectAMINE reagent (Life Technologies, Inc.) and 1-3 µg of total DNA in 1 ml of serum-free OPTI-MEMI (Life Technologies, Inc.), according to the manufacturer's recommendations. After a 12-14-h incubation, an equal volume of Dulbecco's modified Eagle's medium containing 20% fetal bovine serum was added to the transfected cells. 6 h later the cells were lysed and assayed for luciferase activity (35). To assess transfection efficiency, cells were transfected with a cytomegalovirus-beta -galactosidase reporter gene (36), and beta -galactosidase activity was determined and used to normalize luciferase light units.

Yeast Two-hybrid Screen-- To prepare a VP16- alpha T3-1 cDNA fusion library, duplex cDNA was prepared using RNA prepared from alpha T3-1 cells and reagents from Amersham Pharmacia Biotech following the manufacturer's recommendations. The cDNA termini were modified by ligation to an adapter containing a NotI restriction site, and then the cDNA was amplified by the polymerase chain reaction. The amplified cDNA was digested with NotI and subcloned into the NotI site downstream of the VP16 activation domain in the yeast two-hybrid library vector, VP16 (37). A modified bait vector, BTMYeA,2 which allows expression of both a LexA fusion and a second protein, was used for the two-hybrid screen. The LIM domain of Lhx2 (residues 42-182) was isolated by the polymerase chain reaction and subcloned into EcoRI and BamHI sites, which are downstream of the LexA DNA-binding domain of BTMYeA. NLI was cloned downstream of the ADH promoter of the BTMYeA. The strategy of expression of both the LexA-Lhx2 LIM fusion protein and NLI was based on the possible identification of factors that interact with the LIM-NLI complex. However, subsequent analysis of the factors that were isolated in the screen demonstrated that none of the LIM-binding factors were dependent on NLI for binding. The bait and cDNA library plasmids were transformed into the L40 yeast strain (MATa his3Delta 200 trp1-901 leu2-3, 112 ade2 LYS2:: (lexAop)4-His3 URA3::(lexAop)8-lacZ GAL4 gal80) (37) and selected for positive, interacting clones using histidine minus medium in the presence of 30 mM 3-aminotriazole to suppress the background activity of the bait. Further selection was performed on histidine minus medium containing 50 mM 3-aminotriazole.

Immunoprecipitation and Immunoblot Analysis-- For immunoprecipitation studies, alpha T3-1 cells were cultured in 150-mm2 plates and transfected using LipofectAMINE with either pcDNA3 or pcDNA3 directing the expression of FLAG epitope-tagged Lhx2 as described above. 48 h after transfection the cells were collected, and nuclei were isolated and extracted as described previously (1). Nuclear extracts were incubated with M2 FLAG antibody immobilized on agarose beads (Kodak) overnight at 4 °C and subsequently washed five times in 1 ml each of 50 mM Tris, pH 7.8, 150 mM NaCl, and 0.5% Nonidet P-40 (Sigma). The immunoprecipitates were resolved on a denaturing 10% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane using a semi-dry transfer apparatus following the manufacturer's instructions (Bio-Rad). Lhx2 and Lhx3 were detected using polyclonal antibodies. The Lhx2 antibody was prepared by immunizing rabbits with a glutathione S-transferase fusion to a fragment of the coding sequence of mouse Lhx2. The antibody to mouse Lhx3 was a generous gift of Dr. S. Pfaff (38). MRG1 was detected using a polyclonal antibody to MRG1 at a dilution of 1:1000, a generous gift of T. Shioda. GAL4 fusion proteins were detected using monoclonal antibodies (Santa Cruz). Immunoblots were developed using horseradish peroxidase-conjugated secondary antibodies (Sigma), followed by detection with an enhanced chemiluminescence reagent (NEN Life Science Products).

In Vitro Binding Assays-- MBP fusion proteins were expressed in Escherichia coli grown at 30 °C and immobilized on amylose resin as described (39). In vitro binding reactions were performed in 10 mM HEPES, pH 7.4, 150 mM NaCl, and 0.1% Tween-20. Radiolabeled proteins for analysis of binding were generated by in vitro transcription using bacteriophage SP6 or T7 RNA polymerase (40) and translation in a reticulocyte lysate in the presence of [35S]methionine using reagents from Promega. FLAG epitope-tagged p300 was expressed and purified from baculovirus. After incubation of the binding reactions for 2 h at 4 °C, the resin was washed 5 × 1 ml in the binding buffer. Bound proteins were resolved on 10% polyacrylamide denaturing gels and visualized by autoradiography or by Western blotting using the anti-FLAG monoclonal antibody as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Lhx2 and Lhx3 Are Both Present in the alpha T3-1 Gonadotrope-derived Cell Line, and Both LIM Factors Can Activate the alpha -Subunit Promoter-- Previous studies from this laboratory have provided evidence that Lhx2 can bind to the PGBE of the alpha -subunit gene and stimulate alpha -subunit promoter activity (1). The Lhx2 cDNA was isolated from a library prepared from the gonadotrope derived, alpha T3-1 cell line (41), and this cell line was confirmed to contain Lhx2 mRNA (1). More recently it has been shown that alpha T3-1 cells also contain Lhx3 mRNA and that Lhx3 can also activate the alpha -subunit promoter (13). These separate studies raise the possibility that both Lhx2 and Lhx3 may contribute to activation of the alpha -subunit gene. To further explore this possibility we examined the expression of Lhx2 and Lhx3 in alpha T3-1 cells at the protein level. Immunoblots demonstrated that both Lhx2 and Lhx3 are indeed present in extracts of alpha T3-1 cells (Fig. 1A). The ability of these LIM factors to activate the alpha -subunit promoter in heterologous cells was then compared (Fig. 1B). Expression vectors for Lhx2 and Lhx3 were both able to stimulate expression of an alpha -subunit reporter gene. Interestingly, deletion of the LIM domain of Lhx2 eliminated activation of the alpha -subunit reporter gene. Although the role that the LIM domain plays in transcriptional activation has been somewhat controversial, these findings provide evidence that within this specific context, the LIM domain of Lhx2 is necessary for transcriptional activation. The findings that both Lhx2 and Lhx3 are present in alpha T3-1 cells and that both factors can activate the alpha -subunit promoter provide evidence that both Lhx2 and Lhx3 may play a role in alpha -subunit regulation in this cell line. In the present studies we have focused our attention on further characterization of Lhx2. However, it should be noted that both Lhx2 and Lhx3 appear to contribute to transcription of the alpha -subunit gene.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Lhx2 and Lhx3 are present in alpha T3-1 cells, and both LIM factors can enhance alpha -subunit reporter gene activity in heterologous cells. Nuclear extracts from alpha T3-1 cells were resolved by denaturing gel electrophoresis and transferred to a membrane before immunostaining with antibody to either Lhx2 or Lhx3 as indicated (A). To examine the ability of Lhx2 and Lhx3 to enhance alpha -subunit promoter activity, NS20Y cells were transfected with 0.2 µg of a reporter construct containing the -507 to +46 region of the mouse alpha -subunit promoter (B). The cells were also transfected with 0.2 µg of either an empty expression vector or expression vector for Lhx2, Lhx3, or the LIM deletion mutant of Lhx2 as indicated. A cytomegalovirus-beta -galactosidase reporter construct (0.5 µg) was transfected to assess differences in transfection efficiency. Data are reported as the relative luciferase activity from three transfections ± S.E. normalized to beta -galactosidase activity.

The LIM Domain of Lhx2 Contains a Transcriptional Activation Domain-- The preceding experiments offered evidence that the LIM domain of Lhx2 may contain a transcriptional activation domain. To directly evaluate the transcriptional activation potential of the LIM domain of Lhx2, we constructed expression vectors in which the yeast GAL4 DNA-binding domain was fused to the LIM domain of Lhx2. The activity of the GAL4-LIM fusion constructs was assessed by transfection of alpha T3-1 cells. Transcription of the alpha -subunit gene in these cells is stimulated by GnRH (12) through a pathway that involves activation of the mitogen-activated protein kinase (31). In the present studies we have used an expression vector for constitutively active Ras (42) to activate MAPK and stimulate alpha -subunit transcription. In the initial studies, a reporter gene containing five copies of a GAL4-binding site upstream of a minimal promoter linked to luciferase was used to assess the ability of the GAL4-Lhx2 LIM construct to activate transcription (Fig. 2A). We found that the GAL4-Lhx2 LIM construct stimulated reporter gene expression and that reporter gene activity was not further stimulated by Ras (Fig. 2B). Similar results were obtained using a GAL4-Lhx3 LIM construct (data not shown). Thus, when tested with this simple reporter gene, the Lhx2 LIM domain appears to contain a transcriptional activation domain that is not responsive to the MAPK pathway. To examine the specificity of activation, we prepared a GAL4 fusion with muscle LIM protein (MLP). MLP has been shown to bind to the actin cytoskeleton (43, 44) and enhance myogenesis (43, 45). The GAL4-MLP construct had very little effect on reporter gene activity. Thus, transcriptional activation is a property of the LIM domain of the nuclear transcription factor, Lhx2, which is not shared with the LIM domain of MLP. It is likely that structural differences in these LIM domains leads to unique protein-protein interactions mediating different responses. To determine whether the transcription-stimulating activity of the Lhx2 LIM domain was dependent on the intact structure of the LIM domain, cysteine residues 52 and 55, which are involved in zinc binding (18, 19), were mutated to alanine. This mutation, which presumably disrupts the structure of the LIM domain, was found to substantially decrease reporter gene activity. All of the GAL4 fusion proteins were expressed at comparable levels (Fig. 2C).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   The LIM domain of Lhx2 contains a transcriptional activation domain. alpha T3-1 cells were transfected with either 0.2 µg of a reporter construct containing five copies of a GAL4-binding site upstream of the E1b TATA box luciferase reporter (A and B) or an alpha -subunit reporter gene containing the -507 to -205 region of the mouse glycoprotein hormone alpha -subunit gene placed upstream of a minimal TATA box linked to luciferase (D and E) or a mutant alpha -subunit reporter gene in which the PGBE was replaced with a GAL4-binding site (D, F, and G). The cells were also transfected with 0.2 µg of either an empty expression vector control or an expression vector for constitutively active Ras and 0.2 µg of an expression vector for the GAL4 DNA-binding domain alone (GAL4) or a GAL4 DNA-binding domain fusion with muscle LIM protein (GAL4-MLP), with Lhx2 or Lhx3 LIM domains (GAL4-Lhx2 LIM or GAL4-Lhx2 LIM) or an Lhx2 LIM domain mutant in which cysteine residues 52 and 55, which interact with a zinc atom, were replaced with alanine (GAL4-LIM Mut). The cells were also transfected with 0.5 µg of a cytomegalovirus-beta -galactosidase vector to assess differences in transfection efficiency. Data are reported as the relative luciferase activity from three transfections ± S.E. normalized to beta -galactosidase activity. The relative expression of the GAL4 fusion proteins was assessed by immunoblot analysis of nuclear extracts from alpha T3-1 cells, which were transfected with the indicated constructs (C).

We also assessed the ability of the LIM domains of Lhx2 to activate transcription in the context of the alpha -subunit promoter. For these studies the wild type PGBE element of alpha -subunit promoter was replaced with one copy of a GAL4-binding site (Fig. 2D). This allowed GAL4-LIM fusion proteins to be directed to the mutated PGBE in transient transfection studies. As described previously (31), expression of the wild type alpha -subunit reporter gene was induced severalfold by activated Ras (Fig. 2E). Consistent with previous studies (1), replacement of the PGBE with a GAL4-binding site reduced basal expression of the alpha -subunit reporter gene and also reduced the ability of activated Ras to stimulate reporter gene expression in the absence of the GAL4-Lhx2 LIM domain construct (data not shown). Neither the GAL4 DNA-binding domain alone nor the GAL4-MLP fusion were able to activate basal expression or support a Ras response (Fig. 2F). In contrast, the GAL4-Lhx2 LIM fusion construct increased basal reporter gene activity and also supported a Ras response that is similar in magnitude to that obtained with the wild type alpha -subunit construct (Fig. 2, compare E and F). The ability of the GAL4-Lhx2 LIM construct to permit a Ras response with the alpha -subunit reporter is in contrast to failure of this same construct to support a Ras response with the simple 5× GAL4 reporter (Fig. 2B). This observation suggests that within the context of the alpha -subunit gene, the Lhx2 LIM domain cooperates with other factors to enhance the response to Ras and activation of MAPK. The activity of the GAL4-Lhx2 LIM construct was dependent on an intact LIM structure as mutation of crucial cysteine residues within the one zinc finger greatly reduced both basal and Ras-stimulated reporter gene activity. We also compared the ability of the LIM domain of Lhx2 and Lhx3 to activate the modified alpha -subunit reporter gene (Fig. 2G). Expression of GAL4-LIM domain fusions of both Lhx2 and Lhx3 allowed Ras-induced activation of the alpha -subunit reporter gene (Fig. 2G).

Because both cytoplasmic and nuclear LIM domains have been shown to function as protein-protein interaction domains (46, 47), it seems likely that the LIM domain of Lhx2 functions as a transcriptional activation domain through recruiting other factors to the alpha -subunit gene. As an initial characterization of this possibility, we sought to determine whether the Lhx2 LIM domain could inhibit alpha -subunit expression (Fig. 3). For these studies, the wild type alpha -subunit reporter gene was co-transfected with the GAL4-LIM constructs. Because the wild type alpha -subunit reporter gene does not contain GAL4-binding sites, we anticipated that any effects of the GAL4 fusion proteins would be indirect through sequestration of specific proteins. Transfection of GAL4-Lhx2 LIM domain vector substantially inhibited Ras-induced expression of the alpha -subunit reporter in a concentration-dependent manner (Fig. 3A). Comparable effects were seen for the GAL4-Lhx3 LIM construct but not the Lhx2 LIM mutant (data not shown). This effect was specific for the alpha -subunit reporter because the GAL4-Lhx2 LIM construct had little or no effect on the thymidine kinase promoter (Fig. 3B). Similarly, an expression vector for GAL4-MLP had no effect on alpha -subunit gene expression (data not shown), again indicating the specificity of this effect.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of the LIM domain of Lhx2 inhibits the ability of Ras to stimulate alpha -subunit reporter gene activity in a concentration dependent manner. alpha T3-1 cells were transfected with 0.2 µg of either the -507 to -205 wild type alpha -subunit reporter gene (A) or a thymidine kinase luciferase reporter (B) and either 0.2 µg of an empty expression vector control or vector for constitutively active Ras and the indicated amount of a GAL4-Lhx2-LIM domain expression vector. Data are reported as relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency.

To further define the structure-function relationship for the Lhx2 LIM domain, the effects of GAL4 fusion constructs containing the individual LIM domains, designated LIM1 and LIM2, were also tested (Fig. 4B). The second LIM domain (LIM2) was sufficient to permit a response to activated Ras, although the total activity is considerably reduced as compared with the activity of the intact LIM domain. Both LIM domains were expressed at comparable levels (Fig. 4C). This result is consistent with reports suggesting that one LIM domain may be sufficient for interaction with a binding partner, whereas the other LIM domain may function to potentiate binding (25, 44).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   The second LIM subdomain of Lhx2 is sufficient to support Ras-mediated enhancement of alpha -subunit transcription. The wild type alpha -subunit reporter gene (A) or the PGBE to GAL4 site mutant alpha -subunit (B) reporter genes (0.2 µg) were transfected into alpha T3-1 cells with either an empty expression vector control or a vector for constitutively active Ras (0.2 µg). The cells also received 0.2 µg of an expression vector for the GAL4 DNA-binding domain (GAL4) or fusion of the GAL4 DNA-binding domain with the Lhx2 LIM domain (GAL4-Lhx2 LIM) or the first LIM subdomain of Lhx2 (GAL4-LIMa) or the second LIM subdomain of Lhx2 (GAL4-LIMb) as indicated. Data are reported as the relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency. The relative expression of the GAL4 fusion proteins was assessed by immunoblot analysis of nuclear extracts from alpha T3-1 cells, which were transfected with the indicated constructs (C).

Direction of GAL4-NLI to the alpha -Subunit Gene Does Not Mimic the Effects of the GAL4-Lhx2 LIM Domain-- Recent studies have identified NLI as a putative co-activator that binds to the LIM domain of both LIM homeodomain transcription factors and LIM-only nuclear factors (24, 26, 28, 29, 48, 49). Although it is clear that NLI binds to a group of nuclear LIM factors, the functional role of NLI has not yet been fully explored. It is possible that LIM-dependent recruitment of NLI to a promoter directly leads to transcriptional activation. To test this possibility a GAL4-NLI fusion vector was co-transfected with the mutant alpha -subunit reporter in which the PGBE was replaced with a GAL4-binding site (Fig. 5A). GAL4-NLI had little effect on basal reporter gene activity and did not support a Ras response (Fig. 5B). GAL4-NLI also did not increase the activity of the simple 5× GAL4 reporter gene (data not shown), consistent with the observation that NLI does not function as a transcriptional activator in yeast (28). Thus, direction of NLI to the PGBE of the alpha -subunit gene is not sufficient to activate transcription. This finding implies that the function of the LIM domain is not limited to the recruitment of NLI to the promoter. Of course, it remains possible that binding of NLI contributes to the transcriptional activity of the LIM domain.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Directed binding of the nuclear LIM-interacting protein to the PGBE of the alpha -subunit gene does not support a transcriptional response to activated Ras. alpha T3-1 cells were transfected with 0.2 µg of the wild type alpha -subunit (A) or the PGBE to GAL4 mutant alpha -subunit (B) luciferase reporter genes and 0.2 µg of either an empty expression vector control or a vector for constitutively active Ras and 0.2 µg of an expression vector for the GAL4 DNA-binding domain (GAL4) or fusion of the GAL4 DNA-binding domain with the Lhx2 LIM domain (GAL4-Lhx2-LIM) or the nuclear LIM-interacting protein coding sequence (GAL4-NLI) as indicated. Data are reported as the relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency. The relative expression of the GAL4 fusion proteins was assessed by immunoblot analysis of nuclear extracts from alpha T3-1 cells that were transfected with the indicated constructs (C).

The Lhx2 LIM Domain Functionally Cooperates with an Ets Transactivation Domain-- The preceding experiments provide evidence that binding of Lhx2 to the PBGE site contributes to basal and Ras-stimulated transcription of the alpha -subunit gene. Previous studies have demonstrated that a different DNA element, the GnRH-RE, also contributes to GnRH-stimulated and presumably Ras-stimulated activation of the alpha -subunit gene (12). The endogenous factor that binds to the GnRH-RE has not been determined but the element does contain a core binding site for the Ets family of transcription factors. A role for an Ets factor in mediating responses to GnRH and Ras/MAPK activation is consistent with the known ability of several Ets factors to be phosphorylated and activated by the mitogen-activated protein kinase (32, 50, 51). Therefore, we sought to determine whether binding of an Ets transcription factor at the GnRH-RE site is capable of supporting Ras-stimulated transcription. For these studies an alpha -subunit reporter gene was constructed in which the GnRH-RE sequence was replaced with a GAL4-binding site in the context of a wild type PGBE sequence (Fig. 6A). GAL4 fusion genes were constructed with the transactivation domains of Elk1 or a mutant Elk1 in which a crucial MAPK phosphorylation site at serine 383 was mutated to alanine (32). As expected (12), replacement of the GnRH-RE with a GAL4-binding site eliminated the ability of the alpha -subunit gene reporter to respond to activated Ras (Fig. 6C). Transfection of a GAL4-Elk1 fusion vector was able to restore Ras-activated reporter gene activity, whereas the MAPK phosphorylation mutant, Elk1-S383A, was unable to restore the Ras response. Similar results were obtained for GAL4 fusions containing the transactivation domains of two other MAPK-responsive Ets factors, Ets1 (50, 52) and Net (53) (data not shown). Of course this experiment does not identify the endogenous GnRH-RE-binding factor. However, the findings demonstrate that when directed to a site corresponding to the GnRH-RE, Ets factors are capable of contributing to Ras responsiveness of the alpha -subunit gene, presumably through a mechanism involving functional cooperation with a LIM factor binding to the PGBE.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   The Elk1 carboxyl-terminal transcriptional activation domain can contribute to the Ras responsiveness of an alpha -subunit reporter gene and synergize with the LIM domain of Lhx2 to mediate Ras responsiveness. alpha T3-1 cells were transfected with 0.2 µg of either the wild type alpha -subunit reporter gene (A and B) or the GnRH-RE to GAL4 site mutant alpha -subunit reporter (A and C) or a simple reporter gene containing three copies of a composite LexA+GAL4-binding site upstream of minimal promoter linked to luciferase (D and E). The cells were also transfected with 0.2 µg of either an empty expression vector control or a vector for constitutively active Ras and with 0.2 µg of an expression vector for the GAL4 DNA-binding domain (GAL4) or the LexA DNA-binding domain (LEX) or fusion of the GAL4 DNA-binding domain with the Elk1 carboxyl-terminal transcriptional activation domain (GAL4-Elk) or the Elk1 activation domain in which a crucial phosphorylation site at serine 383 has been mutated to alanine (GAL4-Elk-mut) or a fusion of the LexA DNA-binding domain with the Lhx2 LIM domain (LEX-LIM) as indicated. Data are reported as the relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency.

To further investigate the functional cooperation of Lhx2 and Elk1, a simple reporter gene was constructed that contained a multimer of the binding site for the bacterial repressor LexA adjacent to a GAL4-binding site. This construct permits analysis of the combined effect of the Elk-1 and LIM domain fusion proteins on a single promoter (Fig. 6D). The GAL4 and LexA DNA-binding domains alone have little or no transcriptional activity when co-transfected with this reporter. When the GAL4-Elk1 or LexA-Lhx2 LIM fusion constructs were transfected separately, there was little if any increase in either basal or Ras-stimulated activity. It should be noted that when GAL4-Elk1 is tested on a reporter gene containing five copies of a GAL4-binding site, the reporter gene is Ras/MAPK responsive (32). It is not clear whether the lack of Ras responsiveness with the GAL4-Elk1 construct and this reporter is due to the decreased number of binding sites or the different arrangement of the binding sites. Nonetheless, when both GAL4-Elk1 and LexA-Lhx2 LIM were expressed, a substantial synergistic response was observed. This activation was not observed when the GAL4-Elk1-S383A MAPK phosphorylation mutant was co-expressed with LexA-Lhx2 LIM. Thus when the Lhx2 LIM domain and the activation domain of Elk1 are directed to this reporter gene, the response mimics that of the wild type alpha -subunit reporter. Again, these findings are consistent with a model in which transcriptional responses of the alpha -subunit gene to Ras/MAPK activation involves the functional cooperation of Lhx2 and Elk1 or another Ets transcription factor.

Identification of a Factor That Interacts with the Lhx2 LIM Domain-- To identify proteins that may be involved in mediating transcriptional responses to the Lhx2 LIM domain, the yeast two-hybrid assay (37, 54-56) was used to screen for Lhx2 LIM domain-interacting proteins. Approximately 12 million clones representing the alpha T3-1 fusion cDNA library were screened for factors that can interact with the LIM domain of Lhx2. Among the positive, LIM-interacting factors, NLI was detected several times, consistent with previous reports (24, 26, 27). The detection of NLI served as a positive control for the quality of the alpha T3-1 cDNA fusion library and suggested that appropriate conditions were used for the screen. In addition to NLI, a VP16 fusion cDNA corresponding to MRG1 amino acids 1-145 (34) was isolated from the screen. MRG1 is widely expressed in both adult tissues and in the later stages of the developing embryo (57). MRG1 and the closely related melanocyte-specific gene (MSG1) are 24- and 27-kDa nuclear proteins, respectively, that have a highly conserved transcriptional activation domain but lack any known DNA-binding domain (34). In addition, MSG1, but not MRG1, has been shown to interact with the transcription factor Smad4 and may function as a co-activator (58).

The ability of MRG1 to bind to the LIM domain of Lhx2 was tested by several different approaches. An in vitro binding assay was used to determine whether the interaction of the Lhx2 LIM domain and MRG1 was direct. This approach provided evidence that in vitro, an MBP-Lhx2 LIM domain fusion protein was able to bind to full-length MRG1 and NLI but not CREB (Fig. 7). The ability of Lhx2 and MRG1 to associate in vivo was examined by a co-immunoprecipitation experiment. An expression vector for FLAG epitope-tagged Lhx2 was transfected into alpha T3-1 cells, and the tagged Lhx2 was isolated from nuclear extracts by immunoprecipitation. Subsequent immunoblot analysis with anti-MRG1 antibodies (34) demonstrated that endogenous MRG1 was associated with the tagged Lhx2 (Fig. 8A). MRG1 was not immunoprecipitated with the FLAG antibody in cells that were not transfected with the FLAG-Lhx2 construct. Thus, the immunoprecipitation experiments provide evidence that Lhx2 and MRG1 can associate in vivo. Because it is possible that the association of Lhx2 and MRG1 could have occurred after disruption of the cells, we also tested for in vivo interaction using a mammalian two-hybrid assay. GAL4 fusions with the Lhx2-LIM domain or the Lhx3-LIM domain were activated by the VP16 fusion protein containing MRG amino acids 1-145 (Fig. 8B). A GAL4 fusion with MLP or the POU transcription factor, Pit1, were not activated by the VP16-MRG1. Thus, both co-immunoprecipitation studies and the mammalian two-hybrid assay provide evidence for a selective in vivo interaction of MRG1 and the LIM domain of Lhx2 and Lhx3.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Lhx2 can bind to MRG1 in vitro. Radiolabeled MRG1 (A), NLI (B), or CREB (C) were prepared by in vitro transcription and translation and then assayed for the ability to bind to either the MBP or an MBP-Lhx2 LIM fusion protein immobilized on amylose resin. After binding and subsequent washes, the reactions were resolved by denaturing gel electrophoresis, and the proteins visualized by autoradiography. For comparison, 15% of the input labeled protein is also shown (Input).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   In vivo interaction of Lhx2 and MRG1. A co-immunoprecipitation assay was used as a test for the in vivo interaction of the Lhx2 and MRG (A). alpha T3-1 cells were transfected with an expression vector for FLAG epitope-tagged Lhx2 or an empty expression vector. Nuclear extracts were prepared and incubated with monoclonal M2 FLAG antibody immobilized on agarose beads. After binding and subsequent washes the immunoprecipitates were resolved by denaturing gel electrophoresis and transferred to a membrane before immunostaining with antibody to MRG1. The interaction of MRG1 with LIM domains was also tested using a mammalian two-hybrid assay (B and C). alpha T3-1 cells were transfected with 0.2 µg of a reporter construct containing five copies of GAL4-binding sites upstream of the E1b TATA luciferase reporter and 0.2 µg of either an expression vector for the transactivation domain of VP16 only or a fusion of VP16 with residues 1-145 of MRG1 (VP16-MRG1) and with 0.2 µg of an expression vector for the indicated GAL4 fusion proteins. Data are reported as relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency.

MRG1 May Function as a Co-activator to Stimulate alpha -Subunit Glycoprotein Gene Expression-- Transfection of alpha T3-1 cells with an expression vector for MRG1 was found to substantially activate the wild type alpha -subunit reporter construct (Fig. 9A). Importantly, this finding suggests that MRG1 can interact with endogenous factors to enhance alpha -subunit expression. Mutation of the PGBE to a GAL4-binding site disrupted the ability of MRG to stimulate the reporter gene, and MRG responsiveness was restored by transfection of either a GAL4-Lhx2 or -Lhx3 LIM domain expression vector (Fig. 9B). Thus the ability of MRG to activate the alpha -subunit reporter gene was dependent on the presence of the LIM domain at the PGBE site. MRG1 also failed to activate a TK-luciferase construct (Fig. 9C), providing additional evidence that the response is specific.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 9.   An MRG1 expression vector stimulates expression of an alpha -subunit reporter gene. The wild type alpha -subunit luciferase reporter gene (A) or the PGBE to GAL4 site mutant alpha -subunit reporter gene (B) or a reporter gene containing the herpes simplex virus thymidine kinase reporter (C) were transfected into alpha T3-1 cells with either 2.0 µg of an empty expression vector control or a vector directing expression of full-length MRG1. The cells also received 0.2 µg of an expression vector for GAL4 DNA-binding domain (GAL4) or a fusion of the GAL4 DNA-binding domain with the Lhx2 LIM domain (GAL4-Lhx2 LIM) or the Lhx3 LIM domain (GAL4-Lhx3-LIM) as indicated. Data are reported as the relative luciferase activity from three transfections ± S.E. corrected for transfection efficiency.

To begin to understand the mechanisms by which MRG1 functions as a potent transcriptional activator, we tested the ability of MRG1 to bind to the Ets-1 transcription factor, the TATA-binding protein and the widely utilized co-activator, CBP/p300 (Fig. 10). We found that immobilized MRG1 bound both TATA-binding protein and p300 but not Ets-1. The ability of MRG1 to bind to CBP/p300 is consistent with a report that appeared while this manuscript was in preparation demonstrating that an alternatively spliced isoform of MRG1, designated p35srj, binds CBP/p300 both in vitro and in vivo. (59).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 10.   MRG1 can bind to the TATA-binding protein and p300 in vitro. MBP or an MBP-MRG1 fusion protein was immobilized on amylose resin and incubated with radiolabeled Lhx2 (A), radiolabeled Ets-1 (B), radiolabeled TATA-binding protein (C), or FLAG epitope-tagged p300 (D). After washing the resin, the bound proteins were analyzed by denaturing gel electrophoresis and detected by autoradiography (A-C) or immunostaining (D). For comparison, 15% of the input was also analyzed (Input).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

These studies provide evidence that the LIM domain of Lhx2 can function as a transcriptional activation domain and enhance both basal and MAPK pathway-stimulated transcription of the alpha -subunit gene. Interestingly, the LIM domain is a zinc finger structure that forms a highly ordered structure (19, 60). Although there are only a few examples where the structures of transcriptional activation domains have been determined, in at least some cases the activation domain may not be highly structured. For instance the transcriptional activation domain of CREB consists largely of random coil and beta  turns (61) until a specific structure is induced after binding to the co-activator, CBP (62, 63). Presumably the ability of the LIM domain to function as a transcriptional activation domain involves the ability of the zinc finger structure to recruit specific proteins to a promoter.

Several laboratories have demonstrated transcriptional synergy between members of the LIM homeodomain transcription factor family and other transcription factors. Lmx-1 and the basic helix-loop-helix factor, E47, synergistically enhance the activity of the rat insulin mini-enhancer (25, 64). Lhx3 has been shown to bind to the POU factor, Pit-1, and synergistically activate prolactin and thyroid-stimulating hormone gene transcription (13). Previous studies from this laboratory have provided evidence that the PBGE of the alpha -subunit gene, which contains an Lhx2-binding site, synergizes with a separate DNA element, the GnRH-RE, to support both basal and GnRH-stimulated transcription (1, 12). The present studies extend the understanding of how Lhx2 supports synergistic activation of transcription. Our studies provide evidence that the LIM domain in the context of the alpha -subunit promoter is able to enhance Ras-activated transcription in the absence of other functional domains of Lhx2. These findings are consistent with a model in which the LIM domain contacts other transcription factors or co-activators leading to synergistic activation. We have also demonstrated the ability of the LIM domain to synergize with members of the Ets family of transcription factors to mediate Ras responsiveness. In the context of the alpha -subunit gene, the LIM domain of Lhx2 is able to enhance MAPK pathway-activated transcription. However, when directed to a simple promoter containing multiple GAL4-binding sites, a GAL4-Lhx2 LIM domain construct was unable to support a Ras response. These results imply that the Ras response depends on the ability of the Lhx2 LIM domain to functionally cooperate with other factors that are recruited to the alpha -subunit gene promoter.

Several previous studies have concluded that the LIM domain plays a negative role in modulating transcriptional activation. However, the function of the LIM domain has largely been inferred from analysis of the activity of LIM domain deletion mutants. For instance, expression vectors for full-length Xlim-1 have little or no effect on X. laevis development, whereas deletion of the LIM domain results in the formation of a secondary axis (24). Similarly, deletion of the LIM domain of Lhx3 enhances transcriptional activation by this factor in heterologous cells (27). In contrast, the present study as well as recent findings from another laboratory (65) have demonstrated that deletion of the LIM domain can decrease transcription-stimulating activity of LIM homeodomain factors. Although the Xenopus studies described above are consistent with a possible negative modulatory role for the LIM domain, other interpretations are possible. If the LIM domain is the major transcriptional activation domain, then deletion of the LIM domain could create an inactive transcription factor. Displacement of a wild type, active LIM homeodomain factor by the inactive LIM-deleted factor would then inhibit transcription. Deletion of the LIM domain of Xlim-1 may then cause formation of a secondary axis through inhibition of a LIM factor-dependent target gene. However, it has been demonstrated that Xlim-1 contains a carboxyl-terminal transcriptional activation domain (28) distinct from the LIM domain, and therefore it is not clear that deletion of the LIM domain would create a dominant negative form of Xlim-1. In any case, the present studies provide evidence that the LIM domain of Lhx2 can function as a transcriptional activation domain, and this function should be considered in evaluating the activity of LIM homeodomain deletion mutants.

The ability of the LIM domain to function as a transcriptional activation domain likely involves the ability of this structure to recruit transcription factors or co-activators. Several laboratories have identified NLI as a LIM-binding, putative co-activator (24, 26, 27). As with the functional properties of the LIM domain itself, the role of NLI has not been clearly established. The results of several studies suggest that NLI acts to stimulate transcription (27, 28). In contrast, NLI has been shown to inhibit the synergy between Lmx-1 and E47 (29). Moreover, recent genetic studies of apterous in Drosophila suggest that the relative stoichiometry of LIM transcription factors and Chip, the Drosophila ortholog of NLI (66), is critical for proper function (47, 67, 68). Although the present studies do not resolve this issue, the results provide evidence that recruitment of NLI is not sufficient for transcriptional activation. Forced recruitment of GAL4-NLI to a mutant alpha -subunit reporter in which the PGBE was replaced with a GAL4 site was not sufficient for transcriptional activation. If NLI functions as a co-activator, its mechanism of action is probably substantially different than the well studied co-activator, CBP, which contains several transcriptional activation domains (69-71).

We have used a yeast two-hybrid screen to search for LIM-interacting factors that might serve as LIM domain co-activators. The screen led to the identification of MRG1 as a LIM-interacting factor. MRG1 was previously isolated based on sequence similarity to the melanocyte-specific gene, MSG1 (34). Initially, the function of MRG1 and MSG1 was unknown, although both are nuclear proteins containing a conserved transcriptional activation domain, and neither contain a known DNA-binding domain. Recently, evidence has been obtained that MRG1 and MSG1 may function as co-activators that bind to other transcription factors (58, 59)

MRG1 has a number of properties that are consistent with a possible function as a co-activator for Lhx2. MRG1 binds directly to the LIM domain of Lhx2 as determined by an in vitro binding assay. A co-immunoprecipitation assay provided evidence that endogenous MRG1 interacts with Lhx2. Importantly, MRG1 expression enhanced alpha -subunit reporter gene activity in a LIM domain-dependent manner. We found that MRG1 is able to bind to the TATA-binding protein and p300/CBP. Our findings are consistent with a model in which Lhx2 recruits MRG1 to the alpha -subunit promoter, which enhances recruitment of p300/CBP and the TATA-binding protein leading to transcriptional activation. Our findings have similarities and important differences with a report that appeared while this manuscript was in preparation (59). Similar to our findings, it was reported that an alternatively spliced isoform of MRG1, which is termed p35srj, binds p300. However, rather than leading to transcriptional activation, p35srj/MRG1 was able to compete with the hypoxia-inducible factor, HIF-1, for binding to p300 leading to a reduction in HIF-1 activity. Thus, MRG1 and its isoforms may function as a co-activator modulator, capable of mediating p300/CBP recruitment and transcriptional activation in some circumstances or blocking the recruitment of p300/CBP, depending on the nature of specific interactions with individual transcription factors.

    ACKNOWLEDGEMENTS

We thank Dr. Toshi Shioda for the polyclonal antibody to MRG1, Dr. Stan Hollenberg for yeast two-hybrid vectors and protocols for library preparation and screening, and Dr. Richard Goodman and Dr. Phyllis Goldman for the BTMYeA yeast two-hybrid bait vector. We thank Dr. Samuel Pfaff for an antibody to mouse Lhx3 and Dr. Mark Roberson for antibodies to mouse Lhx2 and the expression vector for the GAL4-Lhx2 zinc finger mutant vector. We also thank Shall Jue for technical assistance and Bobbi Maurer for aid in preparing this manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant DK36407 (to R. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by an Oregon Health Sciences Foundation fellowship.

§ To whom correspondence should be addressed: Dept. of Cell and Developmental Biology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97201. Tel.: 503-494-7566; Fax: 503-494-4253; E-mail: maurerr@ohsu.edu.

2 P. Goldman, unpublished data.

    ABBREVIATIONS

The abbreviations used are: GnRH, gonadotropin-releasing hormone; PGBE, pituitary glycoprotein basal element; MBP, maltose-binding protein; MAPK, mitogen-activated protein kinase; MLP, muscle LIM protein; MRG1, melanocyte-specific gene-related gene 1; MSG1, melanocyte-specific gene; NLI, nuclear LIM interactor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Roberson, M. S., Schoderbek, W. E., Tremml, G., and Maurer, R. A. (1994) Mol. Cell. Biol. 14, 2985-2993[Abstract/Free Full Text]
2. Papavasiliou, S. S., Zmeili, S., Khoury, S., Landefeld, T. D., Chin, W. W., and Marshall, J. C. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 4026-4029[Abstract/Free Full Text]
3. Hamernik, D. L., and Nett, T. M. (1988) Endocrinology 122, 959-966[Abstract]
4. Leung, K., Kaynard, A. H., Negrini, B. P., Kim, K. E., Maurer, R. A., and Landefeld, T. D. (1987) Mol. Endocrinol. 1, 724-728[Abstract]
5. Lalloz, M. R. A., Detta, A., and Clayton, R. N. (1988) Endocrinology 122, 1681-1688[Abstract]
6. Andrews, W. V., Maurer, R. A., and Conn, P. M. (1988) J. Biol. Chem. 263, 13755-13761[Abstract/Free Full Text]
7. Wierman, M. E., Rivier, J. E., and Wang, C. (1989) Endocrinology 124, 272-278[Abstract]
8. Dalkin, A. C., Haisenleder, D. J., Ortolano, G. A., Ellis, T. R., and Marshall, J. C. (1989) Endocrinology 125, 917-924[Abstract]
9. Stanley, H. F., Lyons, V., Obonsawin, M. C., Bennie, J., Carroll, S., Roberts, J. L., and Fink, G. (1988) Mol. Endocrinol. 2, 1302-1310[Abstract]
10. Shupnik, M. A. (1990) Mol. Endocrinol. 4, 1444-1450[Abstract]
11. Burrin, J. M., and Jameson, J. L. (1989) Mol. Endocrinol. 3, 1643-1651[Abstract]
12. Schoderbek, W. E., Roberson, M. S., and Maurer, R. A. (1993) J. Biol. Chem. 268, 3903-3910[Abstract/Free Full Text]
13. Bach, I., Rhodes, S. J., Pearse, R. V., II, Heinzel, T., Gloss, B., Scully, K. M., Sawchenko, P. E., and Rosenfeld, M. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2720-2724[Abstract/Free Full Text]
14. Sheng, H. Z., Zhadnov, A. B., Mosinger, B., Jr., Fujii, T., Bertuzzi, S., Grinberg, A., Lee, E. J., Huang, S.-P., Mahon, K. A., and Westphal, H. (1996) Science 272, 1004-1007[Abstract]
15. Freyd, G., Kim, S. K., and Horvitz, H. R. (1990) Nature 344, 876-879[CrossRef][Medline] [Order article via Infotrieve]
16. Karlsson, O., Thor, S., Norberg, T., Ohlsson, H., and Edlund, T. (1990) Nature 344, 879-882[CrossRef][Medline] [Order article via Infotrieve]
17. Way, J. C., and Chalfie, M. (1988) Cell 54, 5-16[CrossRef][Medline] [Order article via Infotrieve]
18. Archer, V. E. V., Breton, J., Sanchez-Garcia, I., Osada, H., Forster, A., Thomson, A. J., and Rabbits, T. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 316-320[Abstract/Free Full Text]
19. Pérez-Alvarado, G. C., Kosa, J. L., Louis, H. A., Beckerle, M. C., Winge, D. R., and Summers, M. E. (1996) J. Mol. Biol. 257, 153-174[CrossRef][Medline] [Order article via Infotrieve]
20. Sánchez-García, I., Osada, H., Forster, A., and Rabbitts, T. H. (1993) EMBO J. 12, 4243-4250[Medline] [Order article via Infotrieve]
21. Taira, M., Jamrich, M., Good, P. J., and Dawid, I. B. (1992) Genes Dev. 6, 356-366[Abstract/Free Full Text]
22. Taira, M., Otani, H., Saint-Jeannet, J.-P., and Dawid, I. B. (1994) Nature 372, 677-679[CrossRef][Medline] [Order article via Infotrieve]
23. Gong, Z., and Hew, C. L. (1994) Biochemistry 33, 15149-15158[CrossRef][Medline] [Order article via Infotrieve]
24. Agulnick, A. D., Taira, M., Breen, J. J., Tanaka, T., Dawid, I. B., and Westphal, H. (1996) Nature 384, 270-272[CrossRef][Medline] [Order article via Infotrieve]
25. Johnson, J. D., Zhang, W., Rudnick, A., Rutter, W. J., and German, M. S. (1997) Mol. Cell. Biol. 17, 3488-3496[Abstract]
26. Jurata, L. W., Kenny, D. A., and Gill, G. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11693-11698[Abstract/Free Full Text]
27. Bach, I., Carrière, C., Ostendorff, H. P., Andersen, B., and Rosenfeld, M. G. (1997) Genes Dev. 11, 1370-1380[Abstract/Free Full Text]
28. Breen, J. J., Agulnick, A. D., Westphal, H., and Dawid, I. B. (1998) J. Biol. Chem. 273, 4712-4717[Abstract/Free Full Text]
29. Jurata, L., and Gill, G. N. (1997) Mol. Cell. Biol. 17, 5688-5698[Abstract]
30. Schoderbek, W. E., Kim, K. E., Ridgway, E. C., Mellon, P. L., and Maurer, R. A. (1992) Mol. Endocrinol. 6, 893-903[Abstract]
31. Roberson, M. S., Misra-Press, A., Laurance, M. E., Stork, P. J. S., and Maurer, R. A. (1995) Mol. Cell. Biol. 15, 3531-3539[Abstract]
32. Marais, R., Wynne, J., and Treisman, R. (1993) Cell 73, 381-383[CrossRef][Medline] [Order article via Infotrieve]
33. Sun, P., Enslen, H., Myung, P. S., and Maurer, R. A. (1994) Genes Dev. 8, 2527-2539[Abstract/Free Full Text]
34. Shioda, T., Fenner, M. H., and Isselbacher, K. J. (1997) Gene (Amst.) 204, 235-241[CrossRef][Medline] [Order article via Infotrieve]
35. de Wet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R., and Subramani, S. (1987) Mol. Cell. Biol. 7, 725-737[Abstract/Free Full Text]
36. MacGregor, G. R., and Caskey, C. T. (1989) Nucleic Acids Res. 17, 2365[Free Full Text]
37. Hollenberg, S. M., Sternglanz, R., Cheng, P. F., and Weintraub, H. (1995) Mol. Cell. Biol. 15, 3813-3822[Abstract]
38. Sharma, K., Sheng, H. Z., Lettieri, K., Li, H., Karavanov, A., Potter, S., Westphal, H., and Pfaff, S. L. (1998) Cell 95, 817-828[CrossRef][Medline] [Order article via Infotrieve]
39. Bedouelle, H., and Duplay, P. (1988) Eur. J. Biochem. 171, 541-549[Medline] [Order article via Infotrieve]
40. Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., and Green, M. R. (1984) Nuc. Acids Res. 12, 7035-7056[Abstract/